As the end of the year approaches, "leaving" has become a lively topic
in the medical circle.
In November, just after the opening, a large number of pharmaceutical companies reported the departure of
senior executives.
Guizhou Sanli: Supervisors resigned
On November 2, Guizhou Sanli announced that the company's board of supervisors recently received a written resignation report submitted by Ms.
Zhao Yini, a supervisor of the company, and Ms.
Zhao Yini applied to resign as a supervisor of the third board of supervisors of the company for personal reasons, and will no longer hold any position
in the company after her resignation.
According to the data, Guizhou Sanli is a modern proprietary Chinese medicine pharmaceutical enterprise
integrating R&D, production and sales.
The company's product line mainly focuses on pediatrics, respiratory system, cardiovascular and cerebrovascular, gastroenterology and other fields
.
According to the third quarterly report of 2022, the company achieved total operating income of 710 million yuan in the first three quarters of 2022, a year-on-year increase of 15.
6%; The net profit attributable to the parent was 104 million yuan, a year-on-year decrease of 7.
4%; Earnings per share were $0.
25
.
China Biopharma: Executive Director Resigns
On November 2, China Biopharmaceutical announced that Wang Shanchun has resigned as an executive director of the company due to his intention to pursue other career developments, effective
November 2, 2022.
According to the data, China Biopharmaceutical is one of the companies of CP Group, and the company's drugs are mainly aimed at the treatment of liver and cardiovascular and cerebrovascular diseases, and are developing drugs
for the treatment of tumors, pain, diabetes, respiratory diseases and other fields.
In 22Q3, the company's revenue increased by about 21.
3% year-on-year; In the first three quarters, cumulative revenue increased by about 10.
5%
year-on-year.
It is reported that at the end of September 2021, the company announced that it would no longer disclose the first quarterly report and the third quarterly report
.
Thalys Medical: Deputy General Manager resigned
On November 1, Thalys Medical announced that the company's board of directors recently received a written resignation report submitted by Mr.
Liu Feng, deputy general manager of the company, and Mr.
Liu Feng resigned from the position of
deputy general manager of the company for personal reasons.
In accordance with the Rules Governing the Listing of Stocks on the Shanghai Stock Exchange and the Articles of Association of the Company, Mr.
Liu Feng's resignation report shall take effect
from the date it is delivered to the Board of Directors.
After Mr.
Liu Feng resigned, he no longer held any position
in the company.
According to the data, the Thalys medical technical service team covers 24 provinces and cities across the country, with 1800+ cooperative suppliers, 1100+ kinds of instruments and equipment, and 51000+ kinds of drugs/consumables/reagents, which can basically achieve the comprehensive coverage of
IVD reagent consumables for the inspection business of cooperative medical institutions.
Its wholly-owned subsidiary Thalys Biotech has independently developed and completed more than 200 technological innovations, 23 national patent authorizations, 180 marketing authorizations for diagnostic reagents, and 2 marketing authorizations for instruments, with a comprehensive conversion rate of more than
90%.
In addition, Thalys Biotech also has the first batch of listed IVD intelligent manufacturing bases in Hunan Province, covering an area of 8000 m²
.
According to the financial report, Celi Medical achieved operating income of 1.
762 billion yuan in the first three quarters, a slight decrease from the same period last year, mainly due to the continuous impact of the epidemic and the expiration and termination of some customers' business contracts; the company's net profit in the third quarter turned from profit to loss, mainly due to factors such as increased expenses and increased credit impairment
.
Celon Pharmaceutical: Deputy General Manager resigned
On November 2, Sailon Pharmaceutical announced that due to personal reasons, Mr.
Tong Yan applied to resign from the position of deputy general manager of the company, and after the resignation, Mr.
Tong Yan will not hold any position
in the company and its subsidiaries.
According to the data, Sailon Pharmaceutical is a modern pharmaceutical enterprise
integrating the research and development, production, marketing and technical services of pharmaceutical intermediates, APIs and preparations.
According to the third quarterly report disclosed by the company, in the first three quarters of 2022, the total operating income was 193 million yuan, a year-on-year increase of 4, and the net profit attributable to the parent was 1.
7 million yuan, a year-on-year decrease of 85.
6%.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
